Compare Amylx Pharmaceuticals Inc (AMLX) vs Roblox Corp (RBLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Roblox Corp — how do they compare? Amylx Pharmaceuticals Inc trades at $23.54 (market cap $2.64B), while Roblox Corp trades at $35.7 (market cap $25.87B). The key difference: Roblox Corp is far larger — about 9.8× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Roblox Corp nearer its low. Which is the better fit depends on your goals.
| AMLX | RBLX | |
|---|---|---|
Market Cap | $2.64B | $25.87B |
Sector | Health | Media |
52-Week High | $24.19 | $141.56 |
52-Week Low | $7.82 | $35.60 |
Enterprise Value | $2.39B | $24.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.
The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.
Roblox (RBLX) trades at $35.33, down 4.64% on the day, amid a bearish technical signal and negative investor sentiment driven by multiple class-action lawsuits. The company shows strong revenue growth, with 2025 revenue reaching $4.89 billion, but remains unprofitable with a net income margin of -17.61%. Recent earnings have beaten expectations, yet management withdrew full-year 2026 guidance, increasing uncertainty.
The outlook is mixed: robust user engagement and revenue growth offer long-term potential, but near-term risks from legal challenges and persistent losses warrant caution. Analyst consensus is a Buy with a $45.67 price target, suggesting upside if execution improves, though volatility from negative news flow may pressure the stock.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Roblox Corp
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →
